Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells |
| |
Authors: | Martin Scheer Uta Drebber Kai Breuhahn Christoph Möckel Tobias Reuther Michael Kern Joachim E. Zöller |
| |
Affiliation: | 1. Department for Oral and Craniomaxillo and Facial Plastic Surgery, University of Cologne, Kerpener Strasse 62, 50931, Cologne, Germany 2. Institute of Pathology, University of Cologne, Joseph-Stelzmann-Strasse 9, 50931, Cologne, Germany 3. Institute of Pathology, Ruprecht-Carls University, Im Neuenheimer Feld 220/221, 69120, Heidelberg, Germany 4. ENT-Department, St. Franziskus Hospital, Sch?nsteinstrasse 63, 50825, Cologne, Germany 5. Department for Oral and Craniomaxillo and Facial Plastic Surgery, Julius-Maximilians University, Pleicherwall 2, 97070, Wuerzburg, Germany
|
| |
Abstract: |
Purpose The inducible enzyme cyclooxygenase-2 (COX-2) catalyzes PGE2 production and plays an important role in the progression of many solid cancers. However, the role of COX-2 expression in cervical lymph node metastases of head and neck cancer has not been clarified yet. Patient and methods We comment on a male patient aged 53 who was admitted to an ENT-department with acute bleeding from an advanced hypopharyngeal carcinoma and a frontotemporal mass. Prior to palliative intended radiotherapy, the metastasis was resected. During the procedure, a small amount of tumor tissue was harvested for primary tumor cell culture. Results COX-2 overexpression was demonstrated in the primary tumor tissue, the metastasis, in the cultured tumor cells by standard immunohistochemistry, as well as cytochemistry. Conclusions A simultaneous expression of COX-2 in head and neck carcinoma was presented for the first time. Besides the prognostic impact in oral carcinogenesis, this COX-2 role of biomarker for aggressive head and neck squamous cell carcinomas should be further evaluated. Additionally, treatment of hypopharyngeal carcinomas with selective COX-2 inhibitors could be beneficial when administered in combination with radiochemotherapy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|